US Merger & Acquisition SEC Filings — August 28, 2026

Completed $243.4M acquisition of ASM on Aug 28, 2026, with a 0.053 share + A$0.13 cash per share structure; the deal closed on schedule per the Jan 21, 2026 Scheme Implementation Deed, signaling strong execution. The use of Section 3(a)(10) exemption avoids SEC registration delays.

Raised $102.3M in IPO (including $2.3M sponsor private placement) but has an accumulated deficit of $2.9M and a going concern warning from auditors—cash burn before any deal is a red flag. No target identified, no substantive discussions.

Priced $75M IPO at $10/unit, trading on Nasdaq under 'RNAQU' from Aug 27, 2026; focused on life sciences (therapeutics, genomics, biomanufacturing). The 1/4 warrant per unit structure offers upside leverage for investors.

Non-redemption agreements to retain up to 1M shares in trust in exchange for up to 250K Pubco shares—a creative structure to avoid trust shrinkage. However, the special meeting was adjourned to Sep 8, 2026, indicating shareholder pushback on the extension.

Drew only $5,000 for its 7th one-month extension (out of 11 permitted), pushing deadline to Sep 29, 2026. The minimal draw suggests sponsor confidence is low; 7 extensions without a deal signals a high risk of liquidation.

Terminated merger with SeeQC on Aug 25, 2026, but secured up to $2M in expense reimbursement upon a future Trigger Event (change of control, IPO, or $100M+ equity raise). The 4-year NDA extension suggests SeeQC may still pursue a deal.

Issued $1.615M secured promissory note to Streeterville Capital at a 7.7% discount ($105K OID + $10K expenses), secured by all assets and IP. The high-cost debt and asset pledge indicate severe liquidity constraints.

The ASM acquisition gives Energy Fuels a vertically integrated rare earth supply chain, critical for US defense and EV supply chains. No insider sales reported, suggesting management confidence in the deal's value creation.

Auditor's report includes a going concern paragraph; accumulated deficit of $2.9M with only $100M in trust (untouchable for ops). The company has no revenue and no target identified—cash burn rate is a critical risk.

7 of 11 permitted extensions used, with only $5,000 drawn for the latest extension. The company has been searching for a deal since at least Jan 2024 (note date). Liquidation probability is high if no deal by Sep 29, 2026.

Merger with SeeQC terminated on Aug 25, 2026, with no disclosed termination fee. Allegro's only recovery is up to $2M in expenses contingent on a future SeeQC event—uncertain and non-guaranteed.

The $1.615M note is secured by ALL assets and IP, with a guarantee from OW Cyber. Default could trigger loss of core intellectual property. The 7.7% OID implies a high cost of capital and distressed credit profile.

Special meeting adjourned to Sep 8, 2026; if shareholders reject the extension, the SPAC must liquidate. The sponsor converting 5.75M Class B shares to Class A upon approval suggests dilution risk for public holders.

As a newly formed SPAC with no operations and no substantive discussions, the 18-24 month deadline clock is ticking. Any delay in finding a target increases the risk of a fire-sale merger or liquidation.

New SPAC with no target identified; the life sciences focus is competitive and requires specialized due diligence. If the market turns risk-off, the $75M trust could face redemptions.

The $243.4M ASM acquisition is a cross-border deal (Australia) with a share+cash structure. Currency risk, regulatory approvals, and integration of ASM's rare earth operations could dilute near-term earnings.

The ASM acquisition creates a vertically integrated rare earth producer at a time when US policy is aggressively supporting domestic critical mineral supply chains. The deal closed on Aug 28, 2026, and Energy Fuels shares may re-rate as the market prices in the strategic value.

New SPAC with a focused mandate in high-growth life sciences subsectors (therapeutics, genomics, precision medicine). The 1/4 warrant per unit structure offers asymmetric upside if a quality target is found.

The non-redemption agreements offer up to 250K Pubco shares for investors who retain shares through a deal closing by Jun 9, 2027. This creates a potential 25% bonus for patient investors.

The 4-year NDA extension and $2M expense reimbursement trigger suggest SeeQC may still pursue a public listing. If SeeQC achieves a $100M+ equity raise or IPO, Allegro receives up to $2M—a potential 10%+ return on current market cap.

With 7 extensions used and only 4 remaining, the SPAC is trading near trust value. If no deal is announced by Sep 29, 2026, investors can redeem at ~$10.10/share (trust value). The current price may offer a small arbitrage.

The use of this exemption for the ASM deal avoids SEC registration costs and delays, allowing faster integration. This could be a template for future M&A in the critical minerals space.

At $10/unit with a $100M trust, this SPAC offers a clean slate for a potential high-quality target. The sponsor's $2.3M private placement aligns incentives. If a target is found in a hot sector, units could trade above trust.

The $1.615M note at a 7.7% discount implies a potential 8.3% yield if the company survives. Streeterville Capital's involvement (known for distressed lending) suggests a turnaround play. However, the asset pledge is a risk.

New SPAC IPOs (NorthStrive, Rainier) raised $177.3M combined, while existing SPACs (Andretti, Constellation, Allegro) face extension votes, terminations, and liquidation risk. The market is rewarding new issuances but punishing legacy SPACs that can't close deals.

Energy Fuels' $243.4M acquisition of ASM is the only completed M&A in this batch, highlighting the strategic importance of rare earth supply chains. Expect more consolidation as US policy incentivizes domestic production.

Intrusion Inc's $1.615M secured note at a 7.7% discount reflects the tight credit conditions for small-cap tech companies. The asset pledge (including IP) is a last-resort financing structure, signaling broader stress in the sector.

Rainier Acquisition Corp's mandate in therapeutics, diagnostics, and genomics aligns with a sector that has seen strong IPO activity. The 1/4 warrant structure is a common feature, offering upside leverage but also dilution risk.

Three SPACs (Andretti, Constellation, Allegro) are struggling to close deals, with Allegro's termination being the most severe. The pattern suggests that SPACs formed in 2024-2025 are running out of time and facing shareholder redemption pressure.

Energy Fuels' use of a scheme of arrangement and Section 3(a)(10) exemption for an Australian target shows the complexity of cross-border M&A. The nominee sale mechanism for certain jurisdictions adds administrative layers.

Special meeting adjourned to Sep 8, 2026 at 10:00 AM ET. Shareholder vote on one-year extension to Sep 9, 2027. Redemption deadline is Sep 3, 2026 at 5:00 PM ET. Watch for redemption levels and vote outcome.

Next extension deadline is Sep 29, 2026. With 7 of 11 extensions used, any announcement of a target or further extension will be critical. Watch for any 8-K filings regarding a business combination.

Monitor for any Trigger Event (change of control, IPO, or $100M+ equity raise) from SeeQC that would trigger the $2M expense reimbursement. The 4-year NDA suggests SeeQC is still active.

Post-acquisition integration of ASM. Watch for Q3 2026 earnings (expected Nov 2026) for initial revenue contribution from ASM assets. Also monitor US critical minerals policy updates.

As a new SPAC, watch for any announcement of a target or letter of intent. The going concern warning means the sponsor must find a deal quickly or face liquidation risk.

Monitor for any default on the Streeterville note or additional financing rounds. The IP security agreement means any distress could trigger loss of core assets. Watch for Q3 2026 earnings for cash burn update.

Units began trading Aug 27, 2026 under 'RNAQU'. Watch for warrant separation date and any early target announcements. The life sciences focus may attract biotech M&A targets.

Monitor redemption rates for Andretti's extension vote. High redemptions could signal broader investor skepticism, impacting other SPACs' ability to close deals.